Bausch Health Cos Inc. (NYSE:BHC) Receives Consensus Rating of “Reduce” from Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been given an average recommendation of “Reduce” by the five research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several equities analysts have issued reports on the stock. Weiss Ratings cut shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Barclays reduced their price objective on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Finally, Royal Bank Of Canada lowered their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th.

Insider Buying and Selling at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the transaction, the director directly owned 49,339 shares in the company, valued at $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Amundi boosted its stake in shares of Bausch Health Cos by 61.7% in the 1st quarter. Amundi now owns 23,983 shares of the company’s stock valued at $130,000 after purchasing an additional 9,148 shares during the last quarter. Royal Bank of Canada grew its holdings in Bausch Health Cos by 24.9% during the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock worth $61,362,000 after acquiring an additional 2,262,894 shares during the period. Whitebox Advisors LLC raised its position in shares of Bausch Health Cos by 3.7% in the 1st quarter. Whitebox Advisors LLC now owns 564,672 shares of the company’s stock worth $3,049,000 after acquiring an additional 20,175 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Bausch Health Cos by 15.5% in the 1st quarter. Lazard Asset Management LLC now owns 53,139 shares of the company’s stock worth $287,000 after acquiring an additional 7,114 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Bausch Health Cos by 10.0% in the 1st quarter. Renaissance Technologies LLC now owns 1,575,772 shares of the company’s stock valued at $8,509,000 after purchasing an additional 143,581 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.17 on Wednesday. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -1.60 and a beta of 0.40. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. The business’s 50-day moving average price is $5.47 and its 200-day moving average price is $6.01. Bausch Health Cos has a 12 month low of $4.80 and a 12 month high of $8.69.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.37 billion. Equities research analysts forecast that Bausch Health Cos will post 4.08 EPS for the current year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.